Urinary Lithogenic Risk Profile in ADPKD Patients Treated with Tolvaptan.

CONCLUSIONS: Tolvaptan treatment is associated with a significantly improved urinary lithogenic risk profile in patients with ADPKD.
PMID: 32527945 [PubMed - as supplied by publisher]

Source: Clinical Journal of the American Society of Nephrology : CJASN - June 10, 2020 Category: Urology & Nephrology Authors: Bargagli M, Dhayat NA, Anderegg M, Semmo M, Huynh-Do U, Vogt B, Ferraro PM, Fuster DG Tags: Clin J Am Soc Nephrol Source Type: research